Clinical Trial Update: Epigenetic Reprogramming in Relapse/Refractory AML [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update reports results of an epigenetic reprogramming therapy for relapse/refractory acute myeloid leukemia, with results posted in Octob…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Epigenetic Reprogramming Therapy (investigational)

Snippet

Sponsor: Therapeutic Advances in Childhood Leukemia Consortium | Conditions: Acute Myelogenous Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2025-10-16